---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-005787"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-04-19T23:59:59+00:00"
generated_at: "2026-06-26T06:34:19.332085+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics cuts 20% of workforce (37 FTE); focuses on CDI and ASD after FDA clinical hold

## Summary
- Reduction of 37 full-time employees (~20% of workforce) approved by board on April 14, 2022.
- Estimates ~$1.1M in one-time severance and related costs, recorded in Q2 2022.
- Restructuring follows FDA clinical hold on CP101 (SARS-CoV-2 donor screening) and pause of chronic hepatitis B program.
- Company has submitted complete response to FDA on clinical hold and awaits feedback.
- Prioritizing recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) programs; Takeda-partnered IBD work continues.

## SEC filing metadata
- accession: 0000950170-22-005787
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/0000950170-22-005787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/fnch-20220414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-005787
- JSON: https://secwatch.observer/filing/0000950170-22-005787.json
- Plain text: https://secwatch.observer/filing/0000950170-22-005787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.